Treating Methamphetamine Use Disorder Without FDA-Approved Medications

Methamphetamine use disorder presents one of the most challenging clinical scenarios in addiction medicine today. While national attention has focused on the opioid epidemic, methamphetamine-related overdose deaths increased nearly 5-fold between 2012 and 2018, with polysubstance use involving stimulants now driving a significant portion of overdose mortality.1

Treatment admissions for methamphetamine use continue to rise, yet our clinical toolkit remains frustratingly limited compared to what we can offer patients with opioid or alcohol use disorders.2 This needs to change, sooner rather than later.

Methamphetamine Use Disorder Has No Standard Medical Detox Protocol

The fundamental challenge is straightforward: we have no FDA-approved medications for methamphetamine use disorder and no established medical detox protocols.3 Clinicians must manage acute withdrawal and support early recovery using only symptomatic treatment and behavioral interventions. This represents a significant disparity in our healthcare system that directly affects patient outcomes.

Methamphetamine’s mechanism of action—massive dopamine release and reuptake inhibition—creates profound neurochemical disruption. Chronic use depletes dopamine stores and downregulates receptors, resulting in severe anhedonia and cognitive impairment.4

Unlike opioid withdrawal, which is time-limited and medically manageable with established protocols, methamphetamine withdrawal can persist for weeks with symptoms including intensive cravings; hypersomnia (sometimes > 20 hours daily initially); depression severe enough to warrant suicide precautions; vivid dreams or nightmares; a slowing of thoughts, actions, and speech; as well as increased appetite.3

The absence of standardized detox protocols means clinical approaches vary significantly between facilities. Some programs provide comprehensive psychiatric monitoring with targeted symptom management, such as antipsychotics for persistent psychosis, sleep aids for the initial hypersomnia phase, and antidepressants when indicated. Others offer minimal medical intervention. This inconsistency contributes to high rates of treatment dropout during the acute withdrawal phase when symptoms are most severe and patients have the fewest internal resources to manage them.5

Post-acute withdrawal syndrome (PAWS) presents additional challenges. Patients may experience episodic cravings, mood instability, cognitive difficulties, and anhedonia for months into recovery.

Executive function deficits can impair patients’ ability to engage with traditional talk therapy or follow complex treatment plans. Neuroimaging studies show that while significant recovery occurs, some changes may persist for a year or more, requiring clinicians to adjust expectations and treatment intensity accordingly.6

Evidence-Based Treatment Options for Methamphetamine Use Disorder: What Clinicians Can Use Now

Current evidence-based approaches rely heavily on behavioral interventions. Contingency management, which provides tangible rewards for verified abstinence, shows the strongest evidence for efficacy.7 Cognitive-behavioral therapy, community reinforcement approaches, and peer support all demonstrate benefits.8

The Matrix Model, an intensive outpatient approach combining these elements, has shown promise specifically for stimulant use disorders.9 However, these interventions require significant patient engagement during a period when neurochemical changes make engagement extraordinarily difficult.

Research into pharmacological options continues, with studies examining various approaches: bupropion and naltrexone combination therapy, modafinil, topiramate, and others targeting different neurotransmitter systems.10, 11, 12 While some show modest promise in reducing use or supporting abstinence, none have achieved FDA approval. The field urgently needs continued investment in medication development research.

Clinicians can optimize outcomes within current limitations by providing a comprehensive assessment for co-occurring disorders, particularly depression, PTSD, and ADHD, which are prevalent in this population.

Extended residential treatment or intensive outpatient programming during the initial months allows for appropriate structure and support during neurological recovery. Harm reduction approaches, including safer use education and connection to services regardless of abstinence status, keep patients engaged and reduce mortality risk.

Addressing methamphetamine use disorder requires clinical creativity, patience, and realistic expectations about recovery timelines. Until we develop effective medications and standardized protocols, clinicians must rely on comprehensive behavioral programming, treatment of co-occurring conditions, and sustained support through the extended recovery period this disorder demands.

References

1. Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999–2018. National Center for Health Statistics; 2020. NCHS Data Brief No. 356.

2. SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. www.samhsa.gov. Published 2021. https://www.samhsa.gov/data/sites/default/files/reports/rpt39443/2021NSDUHNNR122322/2021NSDUHNNR122322.htm

3. Courtney KE, Ray LA. Methamphetamine: An Update on Epidemiology, Pharmacology, Clinical Phenomenology, and Treatment Literature. Drug Alcohol Depend. 2014;143:11-21.

4. Volkow ND, Chang L, Wang GJ, et al. Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence. J Neurosci. 2001;21(23):9414-9418.

5. Fleury MJ, Cao Z, Grenier G, Huỳnh C. Predictors of dropout from treatment among patients using specialized addiction treatment centers. J Subst Use Addict Treat. 2023;150:209062. doi:10.1016/j.josat.2023.209062

6. Volkow ND, Michaelides M, Baler R. The Neuroscience of Drug Reward and Addiction. Physiol Rev. 2019;99(4):2115-2140. doi:10.1152/physrev.00014.2018

7. Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: A systematic review. Drug Alcohol Depend. 2020;216:108307. doi:10.1016/j.drugalcdep.2020.108307

8. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008;27(3):309-317. doi:10.1080/09595230801919494

9. Obert JL, McCann MJ, Marinelli-Casey P, et al. The matrix model of outpatient stimulant abuse treatment: history and description. J Psychoactive Drugs. 2000;32(2):157-164. doi:10.1080/02791072.2000.10400224

10. Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021;384(2):140-153. doi:10.1056/NEJMoa2020214

11. Anderson AL, Li SH, Biswas K, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120(1-3):135-141. doi:10.1016/j.drugalcdep.2011.07.007

12. Moszczynska A. Current and Emerging Treatments for Methamphetamine Use Disorder. Curr Neuropharmacol. 2021;19(12):2077-2091. doi:10.2174/1570159X19666210803091637